Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness ...

Acute ischemic stroke, which occurs due to a blockage in cerebral blood flow, requires prompt intervention with thrombolytic ...

The usage of tenecteplase in patients with acute ischemic stroke was associated with similar effectiveness and safety ...

It has been a year since Manuel Vera, known as Manny, survived an ischemic stroke on February 23, 2024. Vera quickly received ...

A drug has been identified that mimics the effects of physical stroke rehabilitation, offering hope for stroke recovery ...

Tenecteplase (TNKase) is the first new clot-busting drug to be approved in nearly 30 years, with the U.S. Food and Drug ...

(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Ascension Wisconsin recently honored Racine paramedics and the Ascension All Saints Hospital Emergency Department for their swift response in treating a stroke patient on February 17, 2025. The event ...

Background: Tenecteplase improves functional outcomes in acute ischemic stroke (AIS) patients treated 4.5 to 24 h after symptom onset who do not undergo thrombectomy. However, its cost-utility remains ...